We’re excited to announce that Cognivue’s peer-reviewed article, "Validity, reliability and psychometric properties of a computerized cognitive assessment" was published in the World Journal of Psychiatry (WJP).
The article, in WJP’s January 19, 2020 release (Volume 10, Number 1), describes the detailed methodology and data analysis of both pilot and FDA clearance studies (over 500 subjects) that resulted in Cognivue’s FDA clearance as an adjunctive tool to evaluate cognitive function, not a stand-alone diagnostic tool. Cognivue, which is rooted in a unique technology, adaptive psychophysics, had good agreement compared to SLUMS (St Louis University Mental Status exam), good psychometric properties compared to an additional battery of gold-standard neuropsychological tests, and superior test re-test reliability compared to SLUMS – therefore Cognivue can provide an unbiased safe and effective assessment of cognitive function even in early stages of cognitive impairment.
"Cognivue is an important and innovative psychometric tool for cognitive evaluation. This article describes data that are fundamental indicators of its sophistication in evaluating cognitive impairment and cost-effective applicability in clinical practice," says Dr. Reina Benabou, MD, PhD, Cognivue’s Chief Medical Officer.